Frontlight ResearchEarly access
Enrolling by invitationNo phase
Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies
Key facts
- Who runs it
- Ruihua Wei
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 60 people, planned
- Started
- 20 Sept 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 3 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Eyerising RS-200-2A
- Eyerising SLX-1A
- Record updated
- 29 October 2026
Who can take part
- Age
- 18 years to 35 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- 18-35 years old, gender not limited; Obtained informed consent
Who cannot take part
- Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)
- With congenital eye disease, such as congenital cataract, congenital retinal disease
- Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)
- Refractive medium opacity (such as corneal disease, crystal opacity, etc.)
- Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases
- Obvious strabismus and amblyopia
- Bnormal intraocular pressure and clinical significance (IOP <10 mmHg or IOP>21mmHg or binocular IOP difference ≥5mmHg)
- Optic nerve damage or congenital optic nerve dysfunction
- Can not be regularly checked
- The adjustment range is less than 8D or obvious near difficulties
- Other reasons researchers think it is not suitable for inclusion in researchers
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 35 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To explore the effectiveness and safety of repeated exposure to repeated low-intensity red light
The 3 groups in the trial
- The Laser GroupTreatment being tested
Use Eyerising (RS-200-2A), 1 time,2 times or 3 times a day
Treatment: Eyerising RS-200-2A
- The LED GroupTreatment being tested
Use Eyerising(SLX-1A), 2 times a day
Treatment: Eyerising SLX-1A
- ControlNo study treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Study on the Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies for Adult Myopia Treatment
- Criteria questions
- Built from NCT07186088, who can take part
- Record updated
- 29 October 2026